This is a prospective, single center, double arm, randomized, unmasked, First in Human study that aims to evaluate the safety and effectiveness of SakuraBead™ resorbable embolization microspheres in adult patients suffering from pain secondary to plantar fasciitis.

To compare safety and efficacy of SakuraBead with shockwave therapy for the treatment of pain secondary to plantar fasciitis. Treatment will be performed on a total of approximately 45 patients who will be followed up for a period of 6 months.

Inclusion Criteria:

1. Patient is able and willing to provide written informed consent, and
2. Age 18 to 75 years (inclusive), and
3. Clinical diagnosis of PF with proximal plantar fascia thickness greater than 4mm and areas of hypoechogenicity.

Exclusion Criteria:

1. Acute internal derangement of the foot including acute meniscal, ligament or bone injury, or
2. Sensory or motor neuropathy of the feet, or
3. Heel pain caused by stress fractures, nerve entrapment, or inflammatory conditions such as arthritis, gout, or bursitis, or
4. Prior surgical repair or plantar fascia rupture in the involved foot, or
5. Local infection in either foot, or
6. Contraindication to MRI, or
7. Active pregnancy as demonstrated by urine or serum β-hCG or lactating female
8. Unable to provide informed consent or comply with the conditions of the study, or
9. At the discretion of the Principal Investigator